Emerging Trends in Age-Related Macular Degeneration Diagnosis and Treatment

Age-related macular degeneration (AMD) is an eye condition that affects the macula, the central part of the retina responsible for sharp and detailed vision. As populations age across many countries, the number of people at risk of developing AMD is increasing, creating greater demand for early diagnosis, monitoring, and effective treatment.

The age-related macular degeneration market was valued at USD 11.47 Billion in 2025, driven by the rising geriatric population. The market is anticipated to grow at a CAGR of 9.70% during the forecast period of 2026-2035, with the market likely to reach USD 28.95 Billion by 2035. Increasing awareness of eye health, improvements in diagnostic technologies, and the development of advanced treatment options are contributing to the growth of the market.

Rising Geriatric Population Driving Demand

The growing elderly population is one of the primary factors supporting the expansion of the age-related macular degeneration market. The risk of developing AMD generally increases with age, making demographic changes an important consideration for healthcare systems.

As life expectancy increases, more people are living into age groups where age-related eye conditions become more common. This is encouraging healthcare providers to focus on regular eye examinations and early detection.

Greater awareness among older adults is also encouraging individuals to seek eye care before significant vision loss occurs. Early identification can help healthcare professionals determine the appropriate management approach and monitor changes in the condition over time.

Advances in AMD Diagnosis

Diagnostic technology is evolving rapidly and helping ophthalmologists identify retinal changes with greater precision. Modern imaging systems can provide detailed information about retinal structures and support the detection and monitoring of AMD.

Optical coherence tomography (OCT) has become an important tool in retinal care because it enables clinicians to examine detailed cross-sectional images of the retina. Fundus photography, fluorescein angiography, and other imaging technologies can also support diagnosis and disease monitoring.

Artificial intelligence is emerging as another area of interest. AI-based systems can analyse retinal images and identify patterns that may indicate disease. Such technologies could support screening programmes and help clinicians manage increasing patient volumes.

Growing Adoption of Anti-VEGF Treatments

The development and adoption of anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly influenced the treatment landscape for wet AMD. These therapies work by targeting vascular endothelial growth factor, which is associated with abnormal blood vessel growth and leakage in the retina.

Anti-VEGF injections have become an important treatment option for patients with neovascular AMD. Continued research is focused on improving treatment effectiveness while reducing the frequency of injections required by patients.

Longer-acting formulations and alternative delivery methods are being explored to address treatment burden. These developments could improve convenience and support better adherence to treatment schedules.

Focus on Longer-Lasting Treatment Options

One of the major challenges associated with AMD treatment is the need for regular monitoring and, in many cases, repeated treatment. This has encouraged researchers and pharmaceutical companies to explore approaches that can provide longer-lasting effects.

New drug formulations, sustained-release technologies, and alternative drug-delivery methods are being investigated to reduce the frequency of clinical visits and injections.

Longer-lasting treatment options could be particularly valuable for older patients who may face difficulties travelling to healthcare facilities regularly. They may also help healthcare providers manage growing patient populations more efficiently.

Increasing Role of Artificial Intelligence

Artificial intelligence is becoming increasingly relevant in ophthalmology. AI-powered image analysis can help identify retinal abnormalities and support the screening of patients who may require further evaluation.

Machine learning algorithms can be trained to analyse large collections of retinal images and recognise patterns associated with AMD. While these technologies are not intended to replace ophthalmologists, they can potentially assist professionals with screening, prioritisation, and monitoring.

The growing availability of digital health technologies is expected to create further opportunities for AI-supported eye care in the coming years.

Key Trends in the AMD Market

Several developments are expected to influence the age-related macular degeneration market:

• AI-assisted diagnosis: Machine learning and image analysis are supporting the development of automated retinal screening tools.
• Advanced retinal imaging: High-resolution imaging technologies are improving the ability to detect and monitor retinal changes.
• Longer-acting therapies: Research is focusing on treatments that can reduce the frequency of injections.
• Personalised treatment: Patient characteristics and disease progression are increasingly being considered when developing treatment plans.
• Home-based monitoring: Digital tools and remote monitoring technologies may help track changes in vision between clinical visits.

These trends are helping shift AMD management towards earlier detection, continuous monitoring, and more personalised care.

Growing Importance of Early Detection

Early diagnosis can play an important role in managing AMD, particularly because some forms of the condition can progress without obvious symptoms during the initial stages. Regular eye examinations can help identify retinal changes before substantial vision loss occurs.

Public awareness campaigns and improved access to eye-care services can encourage more people, particularly older adults, to undergo routine examinations. Increasing awareness of risk factors may also encourage individuals to take preventive steps related to eye health.

Healthcare professionals are therefore placing greater emphasis on screening, monitoring, and educating patients about changes in vision that should receive medical attention.

Challenges in AMD Diagnosis and Treatment

Despite advancements in diagnosis and treatment, several challenges remain. The cost of advanced therapies and diagnostic equipment can affect access to care, particularly in regions where specialised ophthalmology services are limited.

Treatment adherence is another concern. Some patients may find frequent injections and clinical visits difficult to maintain over extended periods. Transportation challenges, age-related mobility limitations, and healthcare costs can further affect continuity of care.

There is also a need for continued research into treatments that can address different stages and forms of AMD. Developing therapies that provide durable benefits while reducing treatment burden remains an important area of research.

Future Outlook

The future of the age-related macular degeneration market is expected to be shaped by advances in retinal imaging, artificial intelligence, drug delivery, and personalised medicine. As the global population continues to age, the demand for effective diagnosis and treatment is likely to increase.

New therapies designed to provide longer-lasting effects could improve patient convenience, while AI-assisted diagnostic tools may support earlier identification of retinal abnormalities. Improvements in remote monitoring could also make long-term disease management more accessible.

With the market projected to grow from USD 11.47 Billion in 2025 to USD 28.95 Billion by 2035, continued innovation in diagnosis and treatment is expected to create significant opportunities across the AMD healthcare landscape.